Internal Medicine, Critical Care Medicine · San Diego, CA
NPI
1396704698
Since 2006
Specialty
Internal Medicine, Critical Care Medicine
Code 207RC0200X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
4520 Executive Dr
San Diego, CA, 92121
Phone (800) 926-8273
Groups this clinician bills Medicare through
Medicare paid, 2024
$40K
417 services
Medicare patients, 2024
159
Average age 71
Drug cost, 2024
$1.6M
733 prescriptions
Company payments, 2025
$39K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Praveen Akuthota was code 99291 (critical care e&m), 115 times for 46 patients. In total Praveen Akuthota billed 417 services in 28 codes, and Medicare paid $40K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-06-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99291 Critical Care E&M | Facility | 115 | 46 | $167.18 | $19K |
| 99214 Office E&M - Established | Office | 93 | 59 | $98.23 | $9,136 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 80 | 51 | $13.14 | $1,051 |
| 99233 Hospital E&M - Subsequent | Facility | 38 | 27 | $90.77 | $3,449 |
By year: 2022 $32K for 577 services; 2023 $39K for 536 services; 2024 $40K for 417 services.
Medicare prescription drug claims, 2024
In 2024, the drug Praveen Akuthota prescribed most often to Medicare patients was Tezspire (Tezepelumab-Ekko), with 80 prescriptions and refills. In total Praveen Akuthota wrote 733 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tezspire Tezepelumab-Ekko | 80 | 80 | Under 11 | $343K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 77 | 94 | 22 | $2,311 |
| Prednisone Generic | 64 | 70 | 17 | $304 |
| Nucala Mepolizumab | 64 | 73 | Under 11 | $610K |
| Fasenra Pen Benralizumab | 55 | 76 | 11 | $285K |
| Dupixent Pen Dupilumab | 46 | 46 | Under 11 | $163K |
| Montelukast Sodium Generic | 45 | 124 | 17 | $620 |
| Dupixent Syringe Dupilumab | 36 | 37 | Under 11 | $135K |
| Fluticasone Propionate Generic | 27 | 57 | Under 11 | $155 |
| Dulera Mometasone/Formoterol | 25 | 27 | Under 11 | $8,423 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 19 | 45 | Under 11 | $27K |
| Symbicort Budesonide/Formoterol Fumarate | 19 | 27 | Under 11 | $5,649 |
| Breo Ellipta Fluticasone/Vilanterol | 13 | 19 | Under 11 | $6,806 |
| Spiriva Respimat Tiotropium Bromide | 12 | 18 | Under 11 | $9,087 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 11 | 11 | Under 11 | $1,741 |
Brand drugs: 500 claims; generic drugs: 233 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Praveen Akuthota $39K ($39K in general payments such as food, travel and fees) from 8 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $18K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.